The Quality Overall Summary (QOS) is an element of a drug marketing application that provides a substantially condensed summary of the quality-related data provided in the submission. Regulators can use the QOS to more effectively assess applications and more rapidly comprehend the quality information in the context of patient risk, including the proposed control strategy and any other planned steps to mitigate that risk. Patients benefit from the greater assessment efficiency by having improved access to drugs that are designed and manufactured to consistently and safely fulfill claims in the label.
News & Trends
Procurar
Recentes
- Plano de Controlo de Qualidade e Conformidade Legal de SUPLEMENTOS ALIMENTARES: ” Formação muito útil para o desempenho das minhas funções “
- MHRA Registration of medical devices
- The Use of Data in Public Health. Understanding the Potential for Artificial Intelligence in Medicine
- UK Government confirms indefinite recognition of CE marked medical devices
- Methodological Principles for the Assessment of Section 5.1 of the Summary of Product Characteristics
- Good manufacturing practice (GMP) Multistakeholder workshop on expert contributions to artificial intelligence guidance development (Annex 22)
- PIC/S PE 009-18 – Guide to GMP for Medicinal Products | Part I
- EMA Updates Information Page on Bioequivalence Guidelines